Optimizing Drug Inventory: ESIC’s Directive for Addition and Deletion

In a bid to enhance drug procurement efficiency, Employees’ State Insurance Corporation (ESIC) HQRS is gearing up to revamp its Central Rate Contract for drugs listed in DG-ESIC Rate Contracts 149, 150, 151, 152, and 153, expiring on October 31, 2024. Dean, Medical Superintendent, and DIMS are invited to propose additions and deletions. This notification was published on 30/06/2024.

In addition, ESIC institutions are urged to:

  • Solicit departmental heads’ input certifying the uniqueness of proposed generic drugs, absence of substitutes, and documented advantages supported by credible references.
  • Provide one-year local purchase data (from April 1, 2023, to March 31, 2024) endorsed by authorities.

Regarding deletions, institutions are required to furnish procurement figures and reasons via departmental heads. Subsequently, the institution heads will consolidate recommendations, ensuring alignment with departmental inputs and procurement data. Submissions are due by June 10, 2024, via dmcrc@esic.nic.in, adhering to the prescribed formats in PDF and Excel. This directive, sanctioned by the Competent Authority, underscores ESIC’s commitment to optimizing drug procurement processes.